Pioglitazone + Metformin Tablet Franchise in Mumbai Maharashtra

Name: Piobot M Tablet | Pioglitazone 15mg + Metformin 500mg Antidiabetic PCD Franchise
Brand: Piobot M Tablet
Rating: 4.8 (150 reviews)

Antidiabetic PCD Pharma Opportunities in Delhi NCR

Pioglitazone 15mg + Metformin 500mg Tablet Supplier in Chennai Tamil Nadu

Pioglitazone Combination Tablet PCD Franchise in Kolkata West Bengal

Type 2 Diabetes Combination Therapy Distribution in Bangalore Karnataka

Pioglitazone + Metformin Tablet Export Opportunity in Hyderabad Telangana

Home/Products /pioglitazone-15mg-metformin-hydrochloride-ip-500mg-tablet

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

Pioglitazone + Metformin Tablet PCD Pharma Franchise

Pioglitazone Metformin Antidiabetic Medicine Supplier India

Pioglitazone + Metformin Tablet B2B Franchise Opportunity

Piobot M Tablet PCD Pharma Franchise Video

Piobot M Tablet

Composition : Pioglitazone (15mg) + Metformin (500mg)

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹0/-

Please Contact For Best Price

Piobot M Tablet combines Pioglitazone (15mg) and Metformin (500mg) — two well-established oral antidiabetic agents that work synergistically to improve glycemic control in type 2 diabetes mellitus.

Metformin decreases hepatic glucose production and enhances peripheral insulin sensitivity.
Pioglitazone further improves cellular response to insulin and optimizes lipid metabolism.

Together, they help maintain long-term blood-sugar control, prevent diabetes-related complications, and support better cardiovascular outcomes.

Piobot M Tablet belongs to the antidiabetic and endocrinology segment, ideal for patients needing combination therapy. It’s a highly demanded formulation for PCD pharma franchise distribution, third-party manufacturing, and export markets, offering consistent therapeutic outcomes and market potential in India’s rapidly growing diabetes care sector.

About the Product

Metformin decreases hepatic glucose production and enhances peripheral insulin sensitivity.
Pioglitazone further improves cellular response to insulin and optimizes lipid metabolism.

Together, they help maintain long-term blood-sugar control, prevent diabetes-related complications, and support better cardiovascular outcomes.

Common side effects may include mild weight gain, swelling, headache, and fatigue. In rare cases, it can cause fluid retention, heart failure, or liver-related issues. Patients should report any unusual symptoms like shortness of breath, sudden weight gain, or jaundice to their healthcare provider.

Piobot 7.5 Tablet is indicated for the management of type 2 diabetes mellitus, particularly in adults whose blood sugar levels are inadequately controlled through diet and exercise alone. It may be used alone or in combination with other oral antidiabetic agents to improve glycemic control.

Take Piobot 7.5 Tablet exactly as prescribed, with or without food, at a consistent time each day. Regular monitoring of blood glucose, liver function, and weight is important during therapy. Use with caution if you have a history of heart disease, liver problems, or bladder cancer.

Store Piobot 30 Tablet in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep the medication out of reach of children.